The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis

Clinical Infectious Diseases

Volumn 57, Issue 7, 2013, Pages 1001-1004

  Fisher, Cynthia E ^a,b   Stevens, A Michal ^a   Leisenring, Wendy ^a   Pergam, Steven A ^a,b   Boeckh, Michael ^a,b   Hohl, Tobias M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aspergillosis; Aspergillus; Galactomannan; Mortality; Transplant

Indexed keywords

AMPHOTERICIN B DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ECHINOCANDIN; GALACTOMANNAN; POSACONAZOLE; VORICONAZOLE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS USTUS; ASPERGILLUS VERSICOLOR; BLOOD ANALYSIS; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; GALACTOMANNAN INDEX; GRAFT RECIPIENT; HUMAN; LUNG ASPERGILLOSIS; LUNG LAVAGE; MAJOR CLINICAL STUDY; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL;

ASPERGILLOSIS; ASPERGILLUS; GALACTOMANNAN; MORTALITY; TRANSPLANT;

ADULT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; KAPLAN-MEIER ESTIMATE; MALE; MANNANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884403327     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit393     Document Type: Article

References (11)

1. Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50:1559-67.
2. Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 2012; 50:823-30.
3. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34:939-43.
4. Chai LY, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol 2012; 50:2330-6.
5. Hadrich I, Makni F, Cheikhrouhou F, et al. Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis. Pathol Biol 2012; 60:357-61.
6. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48:1255-60.
7. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115:355-62.
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
9. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-40.
10. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110:2744-8.
11. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60:532-8.